144: Court Halts FDA Rule on Lab-Developed Tests: What It Means for Pathology

Send us Fan MailWill FDA rules disrupt the way we diagnose diseases? In this episode, I break down a seismic shift in lab medicine: a federal court has vacated the FDA’s controversial rule classifying lab-developed tests (LDTs) as medical devices. This change carries serious implications for innovation, digital pathology, AI-based diagnostics, and small labs across the U.S.🎧 What You’ll Hear:What LDTs are and why they matter for rare diseases and personalized medicineWhy the FDA rule sparked backlash from the pathology communityWhat the court’s decision means for AI algorithms in digital pathologyWhat’s next: Will Congress revive the VALID Act?How this affects labs, startups, and the future of diagnostic innovationThis podcast is packed with updates every pathology professional should know. 🔍Support the showGet the "Digital Pathology 101" FREE E-book and join us!